Frontiers in Oncology (Aug 2022)
Small but strong: Pivotal roles and potential applications of snoRNAs in hematopoietic malignancies
- Jian Dong,
- Jian Dong,
- Jian Dong,
- Hui Wang,
- Hui Wang,
- Hui Wang,
- Zhaoru Zhang,
- Zhaoru Zhang,
- Zhaoru Zhang,
- Lin Yang,
- Lin Yang,
- Lin Yang,
- Xinyue Qian,
- Xinyue Qian,
- Xinyue Qian,
- Wenchang Qian,
- Wenchang Qian,
- Wenchang Qian,
- Yingli Han,
- Yingli Han,
- Yingli Han,
- He Huang,
- He Huang,
- He Huang,
- Pengxu Qian,
- Pengxu Qian,
- Pengxu Qian
Affiliations
- Jian Dong
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Jian Dong
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Jian Dong
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Hui Wang
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Hui Wang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Hui Wang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Zhaoru Zhang
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Zhaoru Zhang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Zhaoru Zhang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Lin Yang
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Lin Yang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Lin Yang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Xinyue Qian
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xinyue Qian
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Xinyue Qian
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Wenchang Qian
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Wenchang Qian
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Wenchang Qian
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Yingli Han
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Yingli Han
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Yingli Han
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- He Huang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- He Huang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- He Huang
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Pengxu Qian
- Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Pengxu Qian
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Pengxu Qian
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- DOI
- https://doi.org/10.3389/fonc.2022.939465
- Journal volume & issue
-
Vol. 12
Abstract
Small nucleolar RNAs (snoRNAs) belong to a family of noncoding RNAs that are 60-300 nucleotides in length, and they are classified into two classes according to their structure and function: C/D box snoRNAs, playing an essential role in 2’-O-methylation modification on ribosomal RNA; H/ACA box snoRNAs, involved in the pseudouridylation of rRNA. SnoRNAs with unclear functions, no predictable targets, and unusual subcellular locations are called orphan snoRNAs. Recent studies have revealed abnormal expression and demonstrated the pivotal roles of snoRNAs and their host genes in various types of hematological malignancies. This review discusses recent discoveries concerning snoRNAs in a variety of hematological malignancies, including multiple myeloma, lymphoma and leukemia, and sheds light on the application of snoRNAs as diagnostic and prognostic markers as well as therapeutic targets of hematological malignancies in the future.
Keywords
